Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial.

By G. Burmester, R. Blanco, C. Charles-Schoeman, J. Wollenhaupt, C. Zerbini, B. Benda, D. Gruben, G. Wallenstein, S. Krishnaswami, S. Zwillich and 4 more. The Lancet, 2013

644 citations recorded by the source corpus.

Subfields: Hematology, Rheumatology

View Paper: https://www.semanticscholar.org/paper/9dbcbdb98ff9ed97d6da7c0036b5b0405e378705

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Hematology

1. I. McInnes

In Rheumatology

1. I. McInnes
2. J. O’Shea
3. S. Gaffen

Citations in the corpus

• The JAK-STAT Pathway: Impact on Human Disease and Therapeutic Intervention (2015, background): “Patients with disease refractory to both conventional and biologic diseasemodifying antirheumatic drugs (DMARDs) were responsive to tofacitinib (59), and tofacitinib halted radiographic progression of RA (60, 61).”